Form 4: BioXcel Legal Officer Converts RSUs to Stock

Javier Rodriguez, BioXcel Therapeutics' Chief Legal Officer, acquired 68 shares of common stock through the vesting of Restricted Stock Units.

Summary

• Javier Rodriguez, Chief Legal Officer, Senior Vice President, and Corporate Secretary of BioXcel Therapeutics, Inc. (BTAI), acquired a total of 68 shares of common stock.
• On March 14, 2026, 33 Restricted Stock Units (RSUs) granted on March 14, 2022, vested and converted into 33 shares of common stock.
• Following this transaction, Rodriguez beneficially owns 6,828 shares of common stock and 97 RSUs from the 2022 grant.
• On March 15, 2026, 35 Restricted Stock Units (RSUs) granted on March 15, 2023, vested and converted into 35 shares of common stock.
• Following this transaction, Rodriguez beneficially owns 6,863 shares of common stock and 247 RSUs from the 2023 grant.
• Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as it represents a routine insider acquisition of shares, aligning executive interests with shareholders, though it's not a discretionary purchase.

Positives

• The acquisition of common stock by a key executive, Javier Rodriguez, indicates continued alignment of management's interests with those of shareholders.
• The vesting of Restricted Stock Units (RSUs) is a standard component of executive compensation, reflecting the executive's continued employment and contribution to the company.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that routine insider transactions, such as the vesting of Restricted Stock Units, are common occurrences in publicly traded companies. While not indicative of new strategic moves, they reflect the ongoing compensation structure for executives and can signal continued commitment to the company.

Stakeholder Impact

• Shareholders: Increased alignment of executive interests with shareholders through direct stock ownership.
• Employees: Reinforces the company's executive compensation structure, which includes equity incentives.

Next Steps

• Continued vesting of the remaining 97 RSUs from the March 14, 2022 grant on a quarterly basis (6.25% of 521 RSUs per quarter).
• Continued vesting of the remaining 247 RSUs from the March 15, 2023 grant on a quarterly basis (6.25% of 562 RSUs per quarter).

Key Dates

Recommendation

This Form 4 filing details a routine vesting of Restricted Stock Units for a key executive, resulting in the acquisition of a small number of shares. While it indicates continued executive alignment, it does not provide new material information to warrant a change in investment thesis or a strong buy/sell recommendation. It's an expected event within the executive compensation framework.

Keywords

BioXcel Therapeutics, BTAI, Javier Rodriguez, Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Common Stock, Executive Compensation